Besides, long-term follow-up of some epidemiological studies have revealed that 25(OH)D deficient healthy individuals do not show any increment of RA risk (11) . In addition, the immunomodulatory serving dose of 25(OH)D is not exactly defined yet (12) . The key question which now arises is whether the serum values of 25(OH)D are reliable indicators of disease activity in autoimmune diseases with fluctuating courses like RA or not. A few studies investigated the correlation between RA disease activity and vitamin D serum levels (10) (11) (13) (14) (15) (16) (17) (18) . Controversies in the aforementioned study results may stem from several factors affecting 25(OH)D values. So, we decided to evaluate the correlation between the serum values of 25(OH)D, the best indicator of extra renal production of 1,25(OH)D, and disease activity in RA patients.
Methods
Ninety-nine patients diagnosed with RA according to the ACR criteria and sixty-eight healthy controls were included in this study (19) . The study was conducted in Mashhad, Iran, located at 36.20º latitude and 59.35º east longitude. It should be mentioned that Iran is a country with four distinct seasons. The New Year in the country falls in April. During the first six months -April to September-the weather tends to be sunny and warm, and indeed hot. In the second half of the year-October to March-it is usually cold and cloudy. Physical examination, medical history and blood biochemistry were evaluated in all patients to exclude systemic diseases such as chronic kidney or liver disease, malnutrition, and malabsorption (serum albumin below 2.2 mg/dl, cholesterol below 100mg/dl and BMI <18.5kg/m 2 ).
Participants with BMI≥30kg/m 2 were also excluded (regarding the hypothesis which states that 25(OH)D is fat soluble and lower 25(OH)D in overweight individuals may simply be representative of a larger volume of distribution of this vitamin) (20) . Moreover, patients with a history of chronic diarrhea, gastrectomy, patients who received supra physiologic doses of vitamin D (>800U/day) and anti convulsive therapy during a 6-month period prior to the study were omitted from the study, too. All of the patients in this study were treated with supplementary calcium carbonate 1500 mg and 25(OH)D (maximum dose:800U/ day) and hydroxychloroquine 6mg/kg in addition to glucocorticoids and methotrexate. Since we can not stop vitamin D intake or change our patients' treatment regimen to make a homogenous group we selected patients with the same medications which are suspected to affect vitamin D serum levels. The control group was mostly recruited from the patients' acquaintances that lived with them (patient's mother or sisters) to minimize the influence of lifestyle, dressing and nutritional habits on 25(OH)D status in both the case and control groups. The control group was matched for age, gender, and race with the patient group. This control group including normal volunteers was selected to compare the serum values of Vit D in RA patients all according to age and sex matched group.
The blood samples were taken from brachial vein in the morning, and then they were separated by centrifugal method, stored and refrigerated minus 20 degrees. 25(OH) Vitamin D was measured by Elisa. (Immundiagnostik AG, Bensheim, Germany). Anti-CCP antibody serum values more than 5 units were considered elevated according to the manufacturer's instruction (Euroimmune, Germany). Vitamin D status was defined as follows: serum values equal or more than 75nmol/L, 50nmol/L≤25(OH)D< 75nmol/L, and less than 50nmol/L were considered 25(OH)D sufficiency, insufficiency and deficiency, respectively (21) (22) (23) (24) .
Disease activity was assessed in accordance with the Disease Activity Score including 28 joint counts (DA S28 ESR). Components of DAS28 are ESR, patient-assessed visual analogue scale (VAS) (0-100), and swollen and tender joint counts (both from 0-28). Highly active disease was defined as DAS28 > 5.1; moderately active disease 3.2 < DAS28 ≤ 5.1; and slightly active disease DAS28 ≤ 3.2.
All participants signed an informed consent and the local Ethical Committee approved the protocol. The SPSS Version 11.5 was used for the statistical analysis. KolmogorovSmirnov test was used to evaluate the normality of data. Values were expressed as mean±SD for normally distributed variables and median with inter-quartile range (IQR) for non-normally distributed data. Baseline demographics and clinical characteristics were compared between groups using independent samples t-test, Mann-Whitney U test, chisquare, One-Way ANOVA and/or Fisher's exact test when appropriate. Bivariate correlations were assessed using Pearson's and Spearman's correlation coefficients for normally and not-normally distributed data, respectively. Multivariable linear regression analysis was used to determine the interaction between 25(OH)D and DAS. Potential confounding variables were evaluated including 
Results
In this study, 167 (99 RA patients and 68 healthy volunteers) participated. The mean age of the total participants was 42.37±14.07 years. The mean age of patients and controls was 43.94±14.31 and 39.87±13.41 years respectively with no statistical difference, (P=0.074). We did not find any statistical difference in sex distribution among the case and control groups (P=0.09) (table 1).
The mean of disease duration was 5. 
Discussion
The most obvious finding to emerge from this study is that 25 (8, 11). As noted the documents in agreement with the regulatory role of 25(OH)D on the specific facets of human immunity have been shown to be on the rise in recent years and it seems that ,in the future, correction of vitamin D deficiency will be a part of immunomodulation strategies in several autoimmune diseases (5-6, 8, 11-13, 25) . Nevertheless, the association of serum values of 25(OH)D as a surrogate of 1,25(OH)D body supply, with disease activity is not supported by most of the limited studies conducted with this purpose (2, (26) (27) (28) (29) . It is now confirmed that 1,25(OH)D is the most effective metabolite of 25(OH)D at the cellular level of immune cells (2, 28, 30) . However, the direct influence of 25(OH)D on some of innate immune cells should not be ignored. The results of our study are in line with most of the previous studies on the correlation between DAS and 25(OH)D serum levels. There are some explanations for these findings. First, in this study, the patients were under treatment with physiological doses of 25(OH)D according to the recommendations for the osteoporosis prevention (800U/d). Although the patients under treatment with larger doses of 25(OH)D, for at least in the last six months before the study, were excluded, the mean serum values of 25(OH)D were at optimal and probably immunomodulatory levels (75-100nmol/L) (12, 31) . It is now not clear though, in which serum values 25(OH)D plays an immunomodulatory role. However, it is proposed that serum values more than 100 nmol/L may result in pathologic fractures (12, 29) . Therefore, the average serum values of 25(OH)D in our patients, being treated with physiological doses of 25(OH)D, have been recently the accepted range for Vit D sufficiency. Of course, we should not ignore the fact that prescribing hydroxychloroquine as one of the main DMARDs in all of our patients assist in keeping serum values of active metabolites of 25(OH)D at optimal levels (27) . Therefore, it may be concluded that when the serum concentrations of 25(OH)D are sufficient, higher levels of 25(OH)D may not attenuate disease activity. Given the new treatment strategies, some researchers have investigated the clinical efficacy of therapeutic doses of 25(OH)D in the induction of remission of RA that was not effective (21, 32, 33) . Second, most of the studies have proposed that 25(OH)D deficiency is a predisposing factor for the initiation and progression of autoimmune process. For instance, several studies have shown that 25(OH)D serum levels are lower in the newly diagnosed RA patients compared with healthy controls (2-3, 5, 7, 34 ). In the current study, we also found that 25 (21, 33) . Vitamin D deficiency in normal population of our study, especially in women, is unexpectedly high. As mentioned previously, healthy volunteers in this study in contrast to patients, did not receive 25(OH)D. However, the conservative dress code in the country, nutritional 25(OH)D deficiency, which is due to inaccessibility of 25(OH)D enriched food products in our country, and sedentary lifestyles are the main reasons for the high prevalence of 25(OH)D deficiency in our healthy population. Nevertheless, in this study, in which the control group was mostly selected from the patients' relatives who lived with them, to decrease the effect of lifestyle on 25(OH)D status as a confounder, we observed that supplementary physiological doses of 25(OH)D can rise the serum values of 25(OH)D to the accepted normal range. The current study was not without limitations, though. This cross sectional study did not permit a power calculation on the causal relationship between 25(OH)D deficiency and RA activity. Moreover, there were several immeasurable confounders affecting 25(OH)D serum levels that could not be omitted from this study. The strongest point of our study was its precise inclusion and exclusion criteria, which are summarized in table 3.
In brief, in this study, we confirmed that the serum values of 25 
